



Olivier Muller

Kontakt

Olivier Muller

Publikationen (20)

Wagener M, Boeddinghaus J, Gaemperli O, Räber L, Nietlispach F, Meier P, Muller O, Weilenmann D, Jeger R. Trends in Coronary and Structural Heart Interventions in Switzerland over the Last 16 Years and Impact of COVID-19: Insights from the National Swiss PCI Survey. *J Clin Med* 2022; 11

Wenzl F, Kraler S, Ambler G, Weston C, Herzog S, Räber L, Muller O, Camici G, Roffi M, Rickli H, Fox K, de Belder M, Radovanovic D, Deanfield J, Lüscher T. Sex-specific evaluation and redevelopment of the GRACE score in non-ST-segment elevation acute coronary syndromes in populations from the UK and Switzerland: a multinational analysis with external cohort validation. *Lancet* 2022; 400:744-756.

Delabays B, Cavassini M, Damas J, Beuret H, Calmy A, Hasse B, Bucher H, Frischknecht M, Muller O, Méan M, Vollenweider P, Marques-Vidal P, Vaucher J. Cardiovascular risk assessment in people living with HIV compared to the general population. *Eur J Prev Cardiol* 2022; 29:689-699.

Wagener M, Jeger R, Weilenmann D, Räber L, Nietlispach F, Muller O, Meier P, Gämperli O, Cook S, Twerenbold R, On Behalf Of The Swiss Working Group Interventional Cardiology Of The Swiss Society Of Cardiology. Coronary and structural heart interventions in Switzerland 2019. *Swiss Med Wkly* 2021; 151:w20495.

Iglesias J, Windecker S, Valgimigli M, Heg D, Kaiser C, Weilenmann D, Kurz D, Roffi M, Losdat S, Muller O, Pilgrim T. Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial. *Int J Cardiol* 2021; 334:37-41.

Iglesias J, Windecker S, Jüni P, Valgimigli M, Cuculi F, Kaiser C, Weilenmann D, Cook S, Brinkert M, Muller O, Tüller D, Degrauwe S, Roffi M, Heg D, Pilgrim T. Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial. *Cardiovasc Revasc Med* 2021; 34:3-10.

Cimci M, Witassek F, Radovanovic D, Rickli H, Pedrazzini G, Erne P, Muller O, Eberli F, Roffi M. Temporal trends in cardiovascular risk factors prevalence in patients with myocardial infarction. *Eur J Clin Invest* 2020:e13466.

Hermann M, Rickli H, Radovanovic D, Maggiorini M, Roffi M, Muller O, Eberli F, Erne P, Witassek F, AMIS Plus Investigators. Impact of cardiac rehabilitation participation on patient-reported lifestyle changes one year after myocardial infarction. *Eur J Prev Cardiol* 2019:2047487319895429.

Iglesias J, Windecker S, Jüni P, Valgimigli M, Cuculi F, Kaiser C, Weilenmann D, Cook S, Moarof I, Muller O, Rigamonti F, Lanz J, Tüller D, Roffi M, Heg D, Pilgrim T. Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. *J Am Heart Assoc* 2019; 8:e013607.

Iglesias J, Windecker S, Jüni P, Zwahlen M, Oduyayo A, Valgimigli M, Eeckhout E, Losdat S, Stortecky S, Tapponnier M, Kaiser C, Weilenmann D, Moarof I, Kurz D, Roffi M, Heg D, Muller O, Pilgrim T. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. *Lancet* 2019; 394:1243-1253.

Iglesias J, Windecker S, Jüni P, Häner J, Cuculi F, Kaiser C, Weilenmann D, Cook S, Moarof I, Muller O, Noble S, Tüller D, Roffi M, Heg D, Pilgrim T. Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial. *Circ Cardiovasc Interv* 2019; 12:e008024.

Pilgrim T, Jüni P, Eberli F, Hunziker L, Cuculi F, Kaiser C, Weilenmann D, Cook S, Siontis G, Moarof I, Muller O, Tüller D, Roffi M, Heg D, Piccolo R, Windecker S. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. *Lancet* 2018; 392:737-746.

Iglesias J, Windecker S, Jüni P, Eeckhout E, Valgimigli M, Heg D, Tapponnier M, Kaiser C, Weilenmann D, Vuilliamenet A, Kurz D, Roffi M, Zaugg S, Muller O, Pilgrim T. A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. *EuroIntervention* 2018; 14:692-699.

Hugelshofer S, Windecker S, Masci P, Muller O, Degrauwe S, Erne P, Radovanovic D, Rickli H, Pedrazzini G, Pilgrim T, Eberli F, Witassek F, Roffi M, Iglesias J. Impact of total ischemic time on manual thrombus aspiration benefit during primary percutaneous coronary intervention. *Am Heart J* 2018; 204:34-42.

Fournier S, Iglesias J, Eeckhout E, Windecker S, Masci P, Degrauwe S, Zuffi A, Fesselet R, Noble S, Cook S, Erne P, Radovanovic D, Rickli H, Eberli F, Pilgrim T, Roffi M, Benedetto U, Muller O, on behalf on the AMIS Plus Investigators. Circadian dependence of manual thrombus aspiration benefit in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Clin Res Cardiol* 2017

Pilgrim T, Jüni P, Wenaweser P, Blöchliger S, Nietlispach F, Rigamonti F, Taniwaki M, Khattab A, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Muller O, Vuilliamenet A, Tüller D, Roffi M, Heg D, Piccolo R, Windecker S. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction. *EuroIntervention* 2015; 11

Franzone A, Jüni P, Wenaweser P, Stortecky S, Räber L, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Muller O, Vuilliamenet A, Tüller D, Roffi M, Heg D, Pilgrim T, Windecker S. Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial. *Circ Cardiovasc Interv* 2015; 8

Pilgrim T, Jüni P, Wenaweser P, Eberli F, Noble S, Moschovitis A, Fahrni T, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Vuilliamenet A, Muller O, Tüller D, Roffi M, Heg D, Windecker S. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. *Lancet* 2014; 384:2111-22.

Pilgrim T, Jüni P, Heg D, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Vuilliamenet A, Muller O, Tüller D, Roffi M, Windecker S. Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial. *Am Heart J* 2014; 168:256-61.

Wuerzner G, Pechère-Bertschi A, Baumgartner I, Jacob A, Burnier M, Qanadli S, Swiss Society of Hypertension, Swiss Society of Cardiology, Swiss Society of Angiology, Sticherling C, Kaiser C, Waeber B, Muller O, Erne P, Cook S, Sudano I, Lüscher T, Noll G, Kaufmann U, Rickli H, Swiss Society of Cardiovascular and Interventional Radiology. Transcatheter renal denervation for the treatment of resistant arterial hypertension: the Swiss expert consensus. *Swiss Med Wkly* 2014; 144:w13913.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch